

BrainCool AB (publ): an update regarding Medicare's proposal for "fast track" insurance reimbursement with regard to pioneering medical products in the US may benefit BrainCool's products

In the month of June, the US administration and the Centers for Medicare & Medicaid Services (CMS) defined a new approach to establishing "fast track" insurance reimbursement for breakthrough medical products.

The referral period for the new Medicare reimbursement proposal has now expired.

On August 25, Medicare published an editorial ([doi:10.1001/jamahealthforum.2023.2780](https://doi.org/10.1001/jamahealthforum.2023.2780)) in the JAMA Health Forum indicating strong support for establishing a fast track regarding reimbursement for FDA breakthrough devices benefiting the Medicare patient population.

CEO Martin Waleij comments:

-“BrainCool has two breakthrough devices in oncology and stroke, which would benefit from the proposal, however no decision has yet been made public.”

Contacts

For more information

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.

Eminova Fondkommission AB is the company’s Certified Adviser.

Attachments

[BrainCool AB \(publ\): an update regarding Medicare's proposal for "fast track" insurance reimbursement with regard to pioneering medical products in the US may benefit BrainCool's products](#)